Humanigen Inc (HGENQ)

[cowtown jay]

I think lenz retains an advantage over the E7 antibody method of action. Lenz works upstream of E7 by binding GM-CSF. Doing so would eliminate binding the spike proteins of the virus, because the virus would not progress to the point of needing to bind the spike proteins. In addition, it's not just the receptor cells that the virus can target. The virus also shows up in accessory cells, for example.

The lenz/vaccine/anti-viral cocktail will, in my opinion, be so successful, that we will stop the virus prophylactically. That will likely apply to stopping any virus, coronavirus or otherwise, that triggers a hyperactive immune response leading to Cytokine Release Syndrome (CRS).

Also, lenz has already clinically proven it's unmatched ability to prevent and treat cytokine storm in infected patients.

But an additional therapeutic solution, using a different technique to accomplish a similar effect, could be another arrow in the quiver of our therapeutic arsenal, and two is twice as good as one.